Valproate semisodium ER for migraine and cluster headache prophylaxis

Expert Opinion on Drug Metabolism and Toxicology

Volumn 6, Issue 4, 2010, Pages 495-504

  Lovell, Brigitte V ^a   Marmura, Michael J ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Cluster headache; Migraine prophylaxis; Valproate; Valproate semisodium ER

Indexed keywords

AMITRIPTYLINE; CARBAMAZEPINE; CHLORPROMAZINE; CIMETIDINE; COLESTYRAMINE; DIAZEPAM; DULOXETINE; ERYTHROMYCIN; FELBAMATE; GABAPENTIN; NIMODIPINE; NORTRIPTYLINE; PETASITES HYBRIDUS EXTRACT; PHENOBARBITAL; PHENYTOIN; PLACEBO; PRIMIDONE; PROPRANOLOL; PROTRIPTYLINE; RIBOFLAVIN; RIFAMPICIN; TIMOLOL; TOPIRAMATE; UBIDECARENONE; UNINDEXED DRUG; VALPROATE SEMISODIUM; VALPROIC ACID; VENLAFAXINE; WARFARIN; ZIDOVUDINE;

ABDOMINAL PAIN; ANOREXIA; ASTHENIA; BACKACHE; BLURRED VISION; BRAIN DISEASE; BRONCHITIS; CLINICAL TRIAL; CLUSTER HEADACHE; COGNITIVE DEFECT; CONGENITAL MALFORMATION; DIARRHEA; DIPLOPIA; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; HAIR LOSS; HUMAN; HYPERAMMONEMIA; INCREASED APPETITE; LIVER TOXICITY; MIGRAINE; NAUSEA; PANCREATITIS; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PHARYNGITIS; PLASMA CLEARANCE; PROPHYLAXIS; REVIEW; SIDE EFFECT; SOMNOLENCE; TERATOGENICITY; THROMBOCYTOPENIA; TREMOR; VOMITING; WEIGHT GAIN;

CLUSTER HEADACHE; HUMANS; MIGRAINE DISORDERS; VALPROIC ACID;

EID: 77949891230     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425251003693547     Document Type: Review

References (70)

1. Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders. Cephalalgia 2004;24:1-160
2. Lipton RB, Stewart WF, Diamond S, et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001;41(7):646-657
3. Launer LJ, Terwindt GM, Ferrari MD. The prevalence and characteristics of migraine in a population-based cohort: the GEM study. Neurology 1999;53(3):537-542
4. Giffin NJ, Ruggiero L, Lipton RB, et al. Premonitory symptoms in migraine: an electronic diary study. Neurology 2003;60(6):935-940
5. Dodick DW, Silberstein SD. Migraine prevention. Practical Neurol 2007;7(6):383-393
6. Gold L, Black T, Arnold G, et al. Cortical spreading depression- associated hyperemia in rats: involvement of serotonin. Brain Res 1998;783:1983
7. Bradley DP, Smith MI, Netsiri C, et al. Diffusion-weighted MRI used to detect in vivo modulation of cortical spreading depression: comparison of sumatriptan and Tonabersat. Exp Neurol 2001;172:342-353
8. Uddman R, Edvinsson L, Ekman R, et al. Innervation of the feline cerebral vasculature by nerve fibers containing calcitonin gene-related peptide: trigeminal origin and co-existence with substance P. Neurosci Lett 1985;62:131-136
9. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990;28:183-187
10. Russell MB. Epidemiology and genetics of cluster headache. Lancet Neurol 2004;3:279-283
11. Bahra A, May A, Goadsby PJ. Cluster headache: a prospective clinical study with diagnostic implications. Neurology 2002;58:354-361
12. Dodick DW, Rozen TD, Goadsby PJ, et al. Cluster headache. Cephalgia 2000;20:787-803
13. Ekbom K, Monstad I, Prusinski A, et al. Subcutaneous sumatriptan in the acute treatment of cluster headache: a dose comparison study. The Sumatriptan Cluster Headache Study Group. Acta Neurol Scand 1993;88:63-69
14. Kudrow L. Response of cluster headache attacks to oxygen inhalation. Intranasal medications for the treatment of migraine and cluster headache. Headache 1981;21(1):1-4
15. Markley HG. Topical agents in the treatment of cluster headache. Curr Pain Headache Rep 2003;7(2):139-143
16. Meyer JS, Hardenberg J. Clinical effectiveness of calcium entry blockers in prophylactic treatment of migraine and cluster headaches. Headache 1983;23:266-277
17. Ekbom K. Lithium for cluster headache: review of the literature and preliminary results of long-term treatment. Headache 1981;21:132-139
18. Jammes JL. The treatment of cluster headaches with prednisone. Dis Nerv Syst 1975;36:375-376
19. Silberstein S, Tfelt-Hansen P, Dodick DW, et al. Task Force of the International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults. Cephalalgia 2008;28(5):484-495
20. Diener H-C, Dw Dodick, Pj Goadsby, et al. Utility of topiramate for the treatment of patients with chronic migraine in the presence or absence of acute medication overuse. Cephalalgia 2009;29(10):1021-1027
21. Silberstein SD for the US Headache Consortium. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;55:754-762
22. Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007;68(5):343-349
23. Rozen TD, Oshinsky ML, Gebeline CA, et al. Open label trial of coenzyme Q10 as a migraine preventive. Cephalalgia 2002;22:137-141
24. Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology 1998;50:466-470
25. Lipton RB, Gobel H, Einhaupl KM, et al. Petasites hybridus root (butterbur) is an effective preventive treatment for migraine. Neurology 2004;63:2240-2244
26. Silberstein SD, Goadsby PJ. Migraine: preventive treatment. Cephalalgia 2002;22:491-512
27. Silberstein SD. Migraine: preventative treatment. Curr Med Res Opin 2001;17(Suppl 1):s87-93
28. Verrotti A, Salladini C, diMarco G, et al. Extended-release formulations in epilepsy. J Child Neurol 2007;22(4):419-426
29. Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 2002;16(10):695-714
30. Bazil CW, Pedley TA. Clinical pharmacology of antiepileptic drugs. Clinical neuropharmacology. Volume 26, Lippincott Williams and Wilkins, Inc.; 2003. p. 38-52
31. Leao AAP. Spreading depression of activity in cerebral cortex. J Neurophysiol 1944;7:359-390
32. Ayata C, Jin H, Kudo C, et al. Suppression of cortical spreading depression in migraine prophylaxis. Ann Neurol 2006;59(4):652-661
33. Dutta S, Zhang Y. Bioavailability of divalproex extended-release formulation relative to the divalproex delayed-release formulation. Biopharm Drug Dispos 2004;25(8):345-352
34. Freitag FG, Diamond S, Diamond M, et al. Divalproex in the long-term treatment of chronic daily headache. Headache 2001;41:271-278
35. Smith MC, Centorrino F, Welge JA, Collins MA. Clinical comparison of extended-release divalproex versus delayed-release divalproex: pooled data analyses from nine trials. Epilepsy Behav 2004;5:746-751
36. Pellock JM, andWillmore LJ. A rational guide to routine blood monitoring in patients receiving antiepileptic drugs. Neurology 1991;41:961-964
37. Zarate CA Jr, Tohen M, Narendran R, et al. The adverse effect profile and efficacy of divalproex sodium compared with valproic acid: a pharmacoepidemiology study. J Clin Psychiatry. 1999;60(4):232-236
38. Silberstein SD. Divalproex sodium in headache-literature review and clinical guidelines. Headache 1996;36:547-555
39. Pascual J, Leira R, Láinez JM. Combined therapy for migraine prevention? Clinical experience with a beta-blocker plus sodium valproate in 52 resistant migraine patients. Cephalalgia 2003;23(10):961-962
40. Björnsson E. Hepatotoxicity associated with antiepileptic drugs. Acta Neurol Scand 2008;118(5):281-290
41. Driefuss FE, Santilli N, Langer DH, et al. Valproic acid hepatic fatalities: a retrospective review. Neurology 1987;37:379-385
42. Bilo L, Meo R. Polycystic ovary syndrome in women using valproate: a review. Gynecol Endocrinol 2008;24(10):562-570
43. Gomceli YB, Kutlu G, Cavdar L, et al. Valproate-induced hyperammonemic encephalopathy with normal liver function. Epilepsy Behav 2007;10(4):583-587
44. Lheureux PE, Hantson P. Carnitine in the treatment of valproic acid-induced toxicity. Clin Toxicol (Phila) 2009;47(2):101-111
45. Deutsch SI, Burket JA, Rosse RB. Valproate-induced hyperammonemic encephalopathy and normal liver functions: possible synergism with topiramate. Clin Neuropharmacol 2009;32(6):350-352
46. Kalinin W. Suicidality and antiepileptic drugs: is there a link? Drug Saf 2007:30(2):123-142
47. Hesdorffer D, Kanner A. The FDA alert on suicidality and antiepileptic drugs: Fire or false alarm? Epilepsia 2009:50(5):978-986
48. James L, Barnes TR, Lelliott P, et al. Informing patients of the teratogenic potential of mood stabilizing drugs: a case note review of the practice of psychiatrists. J Psychopharmacol 2007;21:815
49. Harden CL, Pennell PB, Koppel BS, et al. American Academy of Neurology; American Epilepsy Society. Management issues for women with epilepsy-focus on pregnancy (an evidence-based review): III. Vitamin K, folic acid, blood levels, and breast-feeding: Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 2009;50(5):1247-1255
50. Meador K, Reynolds MW, Crean S, et al. Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts. Epilepsy Res 2008:81(1):1-13
51. Banach R, Boskovic R, Einarson T, Koren G. Long-term developmental outcome of children of women with epilepsy, unexposed or exposed prenatally to antiepileptic drugs: a meta-analysis of cohort studies. Drug Saf 2010;33(1):73-79
52. Pennell PB. Antiepileptic drug pharmacokinetics during pregnancy and lactation. Neurology 2003;61(6 Suppl 2):S35-42
53. Díaz RA, Sancho J, Serratosa J. Antiepileptic drug interactions. Neurologist 2008;14(6 Suppl 1):S55-65
54. Vinar O, Dvorák A, Vinarová E, et al. Does sodium valproate increase clinical effects of diazepam? Double blind study. Act Nerv Super (Praha) 1989;31(2):106-107
55. Yu HY, Shen YZ, Sugiyama Y, Hanano M. Drug interaction. Effects of salicylate on pharmacokinetics of valproic acid in rats. Drug Metab Dispos 1990;18(1):121-126
56. Freitag FG, Collins SD, Carlson HA, et al. A randomized trial of divalproex sodium extended - release tablets in migraine prophylaxis. Neurology 2002;58:1652-1659
57. Hering, R, Kuritzky A. Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo. Cephalalgia 1992;12:81-84
58. Klapper JA. Divalproex sodium in migraine prophylaxis: a dosecontrolled study. Cephalalgia 1997;17:103-108
59. Jensen R, Brinck T, Olesen J. Sodium valproate has a prophylactic effect in migraine without aura. Neurology 1994;44:647-651
60. Mathew NT, Saper JR, Silberstein SD, et al. Migraine prophylaxis with divalproex. Arch Neurol 1995;52:281-286
61. Apostol G, Lewis DW, Laforet GA, et al. Divalproex sodium extended-release for the prophylaxis of migraine headache in adolescents: results of a stand-alone, long-term open-label safety study. Headache 2009;49:45-53
62. Apostol G, Cady RK, Laforet GA, et al. Divalproex extended-release in adolescent migraine prophylaxis: results of a randomized, double-blind, placebo-controlled study. Headache 2008;48(7):1012-1025
63. Hering R, Kuritzky A. Sodium valproate in the treatment of cluster headache: an open clinical trial. Cephalalgia 1989;9:195-198
64. Gallagher RM, Mueller LL, Freitag FG. Divalproex sodium in the treatment of migraine and cluster headaches. J Am Osteopath Assoc 2002;102:92-94
65. El Amrani M, Massiou H, Bousser MG. A negative trial of sodium valproate in cluster headache: methodological issues. Cephalalgia 2002:22:205-208
66. Wheeler SD. Significance of migrainous features in cluster headache: divalproex responsiveness. Headache 1998;38(7):547-551
67. Magnoux E., Zlotnik, G. Outpatient intravenous dihydroergotamine for refractory cluster headache. Headache 2004;44(3):249-255
68. Peiris JB, Perera GL, Devendra SV, Lionel ND. Sodium valproate in trigeminal neuralgia. Med J Aust 1990;2(5):278
69. Waberzinek G, Marková J, Mastík J. Safety and efficacy of intravenous sodium valproate in the treatment of acute migraine. Neuro Endocrinol Lett 2007;28(1):59-64
70. Stillman MJ, Zajac D, Rybicki LA. Treatment of primary headache disorders with intravenous valproate: initial outpatient experience. Headache 2004;44:65-69